Graybug to Participate in Three Upcoming Medical and Investor Conferences
February 03 2022 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced its participation in three upcoming medical
and investor conferences:
- Angiogenesis, Exudation, and Degeneration 2022 –
Virtual Edition – Veeral Sheth, MD, to
present on “Safety and Durability of Intravitreal Sunitinib Malate
Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO,
Phase 2B)” on February 11, 2022, at 8:30 a.m. ET / 7:30 am CT /
5:30 a.m. PT. Dr. Sheth will discuss the full-data analysis
and highlight patient cases from the 18-month Phase 2b ALTISSIMO
trial of GB-102 for the treatment of wet age-related macular
degeneration, Graybug’s proprietary formulation of sunitinib malate
injected twice-a-year intravitreally.“The 18-month ALTISSIMO data
analysis confirmed the sustained duration of GB-102 1 mg beyond six
months in a masked and controlled Phase 2b trial, and we are
encouraged that the majority of patients volunteering for extended
observation achieved a treatment duration of at least 12 months,
while maintaining their visual acuity and central retinal
thickness,” said Veeral Sheth, MD, MBA, FACS, Partner &
Director of Clinical Trials, University Retina, Chicago, IL.
- 11th Annual Glaucoma 360 New Horizons Forum – Fred
Guerard, PharmD, Chief Executive Officer of Graybug
Vision, to present company overview and report on recent advances
with GB-401 in primary open angle glaucoma, as part of the “New
Horizons in Drugs and Drug Delivery” panel on February 11, 2021, at
11:39 a.m. ET / 8:39 a.m. PT. The event will be held virtually and
in-person at the Grand Hyatt Union Square in San Francisco,
CA.
- 11th Annual SVB Leerink Global Healthcare Conference
– Fred Guerard, PharmD, to participate in
virtual fireside chat on February 17, 2022, at 9:20 a.m. ET / 6:20
a.m. PT.
Available webcasts will be posted in the Investors and Media
section of the company’s website at
https://investors.graybug.vision/news-events/events-presentations.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a formulation of the pan-vascular
endothelial growth factor (VEGF) inhibitor, sunitinib malate
targeting a six-month or longer dosing regimen, inhibits multiple
neovascular pathways for the intravitreal treatment of retinal
diseases, including wet age-related macular degeneration. Graybug’s
other product candidates developed using its proprietary
technologies also include GB-401, an injectable sustained release
formulation of a beta-adrenergic blocker prodrug, for primary
open-angle glaucoma, with a dosing regimen of once every six months
or longer. Founded in 2011 on the basis of technology licensed from
the Johns Hopkins University School of Medicine, Graybug has
offices in Redwood City, California, and in Baltimore, Maryland.
For more information, please visit www.graybug.vision.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995 including, but not limited
to, statements regarding the company’s clinical pipeline, its
ability to advance GB-102, GB-401, or any future product candidate
through preclinical or clinical development, its ability to achieve
its anticipated milestones within the timing outlined above or at
all, its ability to conduct planned operations within the evolving
constraints arising from the COVID-19 pandemic, and the timing,
cost, and results of its clinical trials. Forward-looking
statements are subject to risks and uncertainties that may cause
the company’s actual activities or results to differ significantly
from those expressed in any forward-looking statement, including
risks and uncertainties described under the heading “Risk Factors”
in the company’s annual report on Form 10-K filed for the year
ended December 31, 2020, in its subsequent quarterly reports on
Form 10-Q, and in the other reports the company files from time to
time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to revise or
update any forward-looking statements to reflect events or
circumstances after the date hereof.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024